Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TARS 
Tarsus Pharmaceuticals Inc (TARS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: TARS (3-star) is a WEAK-BUY. BUY since 25 days. Simulated Profits (3.16%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $76
1 Year Target Price $76
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 160.33% | Avg. Invested days 45 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.08B USD | Price to earnings Ratio - | 1Y Target Price 76 |
Price to earnings Ratio - | 1Y Target Price 76 | ||
Volume (30-day avg) 8 | Beta 0.82 | 52 Weeks Range 30.23 - 59.76 | Updated Date 09/14/2025 |
52 Weeks Range 30.23 - 59.76 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -31.13% | Operating Margin (TTM) -21.61% |
Management Effectiveness
Return on Assets (TTM) -14.06% | Return on Equity (TTM) -31.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1774991272 | Price to Sales(TTM) 7.05 |
Enterprise Value 1774991272 | Price to Sales(TTM) 7.05 | ||
Enterprise Value to Revenue 6.01 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 42214100 | Shares Floating 30378537 |
Shares Outstanding 42214100 | Shares Floating 30378537 | ||
Percent Insiders 3.17 | Percent Institutions 118.17 |
Upturn AI SWOT
Tarsus Pharmaceuticals Inc
Company Overview
History and Background
Tarsus Pharmaceuticals, Inc. was founded in 2017 and is focused on developing and commercializing novel therapeutic candidates to address unmet needs in ophthalmic conditions. It went public in 2020.
Core Business Areas
- Pharmaceutical Development: Focused on developing and commercializing innovative therapies for ophthalmic conditions.
- Commercialization: Bringing developed products to market and managing their sales and distribution.
Leadership and Structure
The leadership team includes executives in areas such as research and development, clinical operations, and commercial strategy. The organizational structure is typical for a biotech company, with departments dedicated to research, clinical trials, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- XDEMVY (lotilaner ophthalmic solution) 0.25%: XDEMVY is approved for the treatment of Demodex blepharitis. Revenue data is still building as the product was recently launched. Competitors include traditional lid hygiene products but none are FDA approved for the same indication. XDEMVY has established itself as the market leader for its target condition, Demodex blepharitis. Tarsus is the only company with an FDA-approved solution for Demodex blepharitis
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in ophthalmology, is characterized by high regulatory hurdles, significant research and development costs, and competition from both branded and generic drugs. There is a growing demand for novel treatments for various eye conditions.
Positioning
Tarsus is positioned as an innovative player in the ophthalmic pharmaceutical market, with a focus on developing and commercializing novel therapies for underserved conditions. Their competitive advantage lies in their novel approach to treating Demodex blepharitis, establishing them as a leader in this space.
Total Addressable Market (TAM)
The total addressable market for Demodex blepharitis is estimated to be substantial, with millions of patients affected. Tarsus is positioned to capture a significant portion of this market with XDEMVY.
Upturn SWOT Analysis
Strengths
- First and only FDA-approved treatment for Demodex blepharitis
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a single product (XDEMVY) for revenue
- High marketing and sales expenses associated with product launch
- Relatively small company size compared to established pharmaceutical giants
Opportunities
- Expanding the label of XDEMVY to other indications
- Developing new products for other ophthalmic conditions
- Potential for partnerships or acquisitions to expand product pipeline
Threats
- Competition from other companies developing treatments for blepharitis
- Regulatory hurdles and potential delays in product approval
- Pricing pressures from insurance companies and pharmacy benefit managers
Competitors and Market Share
Key Competitors
- ALVR
- AGN
- VRX
Competitive Landscape
Tarsus Pharmaceuticals, Inc. has a competitive advantage with its first-in-class treatment for Demodex blepharitis. However, larger pharmaceutical companies have broader product portfolios and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the development and approval of XDEMVY.
Future Projections: Future growth is expected to be driven by increased sales of XDEMVY and the potential development of new products.
Recent Initiatives: Recent initiatives include the commercial launch of XDEMVY and efforts to expand its market reach.
Summary
Tarsus Pharmaceuticals is a promising company with a novel, FDA-approved treatment for Demodex blepharitis. While its reliance on a single product represents a risk, there are significant opportunities for growth through expanded indications and new product development. The company faces competition from larger pharmaceutical players. Overall, Tarsus has potential, but success hinges on continued market penetration of XDEMVY and successful pipeline development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (Estimates)
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tarsus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2020-10-16 | Co-Founder, President, CEO & Chairman Dr. Bobak R. Azamian M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 323 | Website https://www.tarsusrx.com |
Full time employees 323 | Website https://www.tarsusrx.com | ||
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.